Dementia with Lewy bodies

Current Opinion in Neurology

Volumn 9, Issue 4, 1996, Pages 271-275

  Kosaka, Kenji ^a   Iseki, Eizo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; HUMAN; LEWY BODY; MOLECULAR BIOLOGY; NEUROPATHOLOGY; REVIEW; SENILE DEMENTIA;

EID: 0029743757     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199608000-00005     Document Type: Review

References (43)

1. Kosaka K: Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol 1978, 42:127-134.
2. Kosaka K, Yoshimura M, Ikeda K, Budka H: Diffuse type of Lewy body disease. Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - a new disease? Clin Neuropathol 1984, 3:185-192.
3. Kosaka K: Diffuse Lewy body disease in Japan. J Neurol 1990, 237:197-204.
4. Gibb WRG, Esiri MM, Lees AJ: Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987, 110:1131-1153.
5. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK: Senile dementia of Lewy body type. A clinically and neuropathologically distinct type of Lewy body dementia in the elderly. J Neurol Sci 1990, 95:119-139.
6. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hoffstetter R, Klauber M et al.: The Lewy body variant of Alzheimer's disease: a clinical and pathological entity. Neurology 1990, 40:1-8.
7. Kosaka K, Iseki E: Diffuse Lewy body disease within the spectrum of Lewy body disease. Proceedings of International Workshop on Lewy Body Dementia. Pathology 1995, 27:1-13.
8. Ince PG, McArthur FK, Bjertness E, Torvik A, Candy JM, Edwardson JA: Neuropathological diagnoses in elderly patients in Oslo: Alzheimer's disease, Lewy body disease, vascular lesions. Dementia 1995, 6:162-168.
9. McKeith IG, Galasko D, Wilcock GK, Byrne J: Lewy body dementia - diagnosis and treatment. Br J Psychiatry 1995, 167:709-717.
10. Louis ED, Goldman JE, Powers JM, Fahn S: Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord 1995, 10:188-194.
11. Byrne EJ, Lenox G, Godwin-Austen RP: Dementia associated with cortical Lewy bodies. Proposed diagnostic criteria. Dementia 1991, 2:283-284.
12. McKeith IG, Perry RH, Fairbairn AF: Operational criteria for senile dementia of the Lewy body type (SDLT). Psychol Med 1992, 22:911-922.
13. Sahgal A, McKeith IG, Galloway PH, Tasker N, Steckler T: Do differences in visuospatial ability between senile dementia of the Alzheimer and Lewy body types reflect differences solely in mnemonic function? J Clin Exp Neuropsychol 1995, 17:35-43.
14. Kosaka K, Oyanagi S, Matsushita M, Hori A: Presenile dementia with Alzheimer, Pick and Lewy body changes. Acta Neuropathol 1976, 36:221-233.
15. Odawara T, Iseki E, Kosaka K, Haga C, Ikeda K: Incidence and distribution of senile plaques and neurofibrillary tangles in late-onset diffuse Lewy body disease. Neuropathology 1994, 14:7-11.
16. Lippa CF, Smith TW, Nee L, Robitaille Y, Crain B, Dickson D, Pulaski Salo D, Pollen DA: Familial Alzheimer's disease and cortical Lewy bodies: is there a genetic susceptibility factor? Dementia 1995, 6:191-194.
17. de Vos RAI, Jansen ENH, Stam FC, Ravid R, Swaab DF: 'Lewy body disease': clinico-pathological correlation in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 1995, 97:13-22.
18. Wakabayashi K, Hansen LA, Masliah E: Cortical Lewy body-containing neurons are pyramidal cells: imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathol 1995, 89:404-408. The authors showed by using an immunostaining method that cortical Lewy body-containing neurons are pyramidal cells.
19. Smith MC, Mallory M, Hansen LA, Ge N, Masliah E: Fragmentation of the neuronal cytoskeleton in the Lewy body variant of Alzheimer's disease. NeuroReport 1995, 6:673-676.
20. Nishiyama K, Murayama S, Shimizu J, Ohya Y, Kwak S, Asayama K, Kanazawa I: Cu/Zn Superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study. Acta Neuropathol 1995, 89:471-474. Lewy bodies in Parkinson's disease were shown to be immunostained with an antibody against Cu/Zn Superoxide dismutase.
21. Dickson DW, Ruan D, Crystal H: Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemlstry of CA2-3 neurites specific to DLBD. Neurology 1991, 41:1402-1409.
22. Kim H, Gearing M, Mirra SS: Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies. Neurology 1995, 45:1768-1770.
23. Iseki E, Odawara T, Suzuki K, Kosaka K, Akiyama H, Ikeda K: A pathological study of Lewy bodies and senile changes in the amygdala in diffuse Lewy body disease. Neuropathology 1995, 15:112-116. The authors showed in detail the distribution and incidence of Lewy bodies and senile changes in amygdala in DLBD patients.
24. Van Gool D, Strooper B, Leuven FV, Dom R: Amyloid precursor protein accumulation in Lewy body dementia and Alzheimer's disease. Dementia 1995, 6:63-68.
25. Smith TW, Lippa CF: Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. J Neuropathol Exp Neurol 1995, 54:297-303.
26. Odawara T, Iseki E, Kosaka K, Akiyama H, Ikeda K, Yamamoto T: Investigation of tau-2 positive microglia-like cells in the subcortical nuclei of human neurodegenerative disorders. Neurosci Lett 1995, 192:145-148.
27. Mann DMA, Snowden JS: The topographic distribution of brain atrophy in cortical Lewy body disease: comparison with Alzheimer's disease. Acta Neuropathol 1995, 89:178-183.
28. Williams TL, Shaw PJ, Lowe J, Bates D, Ince PG: Parkinsonism in motor neuron disease: case report and literature review. Acta Neuropathol 1995, 89:275-283.
29. Hedera P, Lerner AJ, Castellani R, Friedland RP: Concurrence of Alzheimer's disease. Parkinson's disease, diffuse Lewy body disease, and amyotrophic lateral sclerosis. J Neurol Sci 1995, 128:219-224.
30. Hainfellner JA, Pilz P, Lassmann H, Ladurner G, Budka H: Diffuse Lewy body disease as substrate of primary lateral sclerosis. J Neurol 1995, 242:59-63.
31. Kosaka K, Iseki E, Odawara T, Yamamoto T: Cerebral type of Lewy body disease - a case report. Neuropathology 1996, 16:72-75. The authors report the first patient with progressive dementia but without parkinsonism, the neuropathological feature of which was the presence of numerous cortical Lewy bodies without Parkinson pathology.
32. Perry EK, Morris CM, Court JA, Cheng A, Fainbairn AF, McKeith IG, Irving P, Brown A, Perry RH: Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995, 64:385-395. High-affinity nicotine binding was examined autoradiographically in brain regions most severely affected in ATD, DLB, and Parkinson's disease. The authors pointed out that loss or downregulation of the receptor may precede neurodegeneration.
33. Mantle D, Falkous G, Ishiura S, Perry RH, Perry EK: Comparison of cathepsin protease activities in brain tissue from normal cases and with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. J Neurol Sci 1995, 131:65-70.
34. Scot HL, Tannenberg AE, Dodd PR: Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J Neurochem 1995, 64:2193-2202.
35. Lippa CF, Smith TW, Saunders AM, Crook R, Pulaski Salo D, Davies P, Hardy J, Roses AD, Dickson D: Apolipoprotein E genotype and Lewy body disease. Neurology 1995, 45:97-103. The relation between apoE genotype and neuropathology was studied in patients with DLB. The authors suggest that apoE genotype may affect neuropathology in DLB but that it may not have a major direct effect on Lewy body formation.
36. Saitoh T, Xia Y, Chen X, Masliah E, Galasko D, Shults G, Thai LJ, Hansen LA, Katzman R: The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol 1995, 37:110-112. The authors reported a higher representation of the cytochrome P450 CPY2D6 mutant B allele in LBV than in ATD and suggested that this allele is a risk factor for both Parkinson's disease and LBV but not for ATD.
37. Chagnon P, Betard C, Robitaille Y, Cholette A, Cauvreau D: Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. NeuroReport 1995, 6:711-715.
38. de la Monte SM, Ng SC, Hsu DW: Aberrant GAP-43 gene expression in Alzheimer's disease. Am J Pathol 1995, 147:934-946.
39. Allen RL, Walker Z, O'Ath PJ, Katona CL: Risperidone for psychotic and behavioural symptoms in Lewy body dementia [Letter]. Lancet 1995, 346:185. The authors reported that low doses of risperidone produced useful anti-psychotic effects in three patients with DLB.
40. •] these authors described neuroleptic sensitivity to risperidone in three patients with DLB.
41. Perry EK, Haroutunian V, Davis KL, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, McKeith IG, Perry RH: Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. NeuroReport 1994, 5:747-749.
42. Levy R, Egger S, Griffiths M, Perry EK, Honavar M, Dean A, Lantos P: Lewy bodies and response to tacrine in Alzheimer's disease [Letter]. Lancet 1994, 343:176.
43. Liberini P, Memo M, Spano P: Lewy body pathology and heterogeneity of Alzheimer's disease [Letter]. JAMA 1995, 274:1199. The authors hypothesized that the subgroups of Alzheimer's disease patients who responded positively to tacrine are patients affected by DLB either with or without concomitant Alzheimer's disease.